E

Emcure Pharmaceuticals Ltd
NSE:EMCURE

Watchlist Manager
Emcure Pharmaceuticals Ltd
NSE:EMCURE
Watchlist
Price: 1 076.05 INR 0.34% Market Closed
Market Cap: 203.8B INR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

EMCURE Price Targets Summary
Emcure Pharmaceuticals Ltd

Wall Street analysts forecast EMCURE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for EMCURE is 1 565.7 INR with a low forecast of 1 454.4 INR and a high forecast of 1 732.5 INR.

EMCURE Lowest Forecast
Wall Street Target
1 454.4 INR
35% Upside
EMCURE Average Forecast
Wall Street Target
1 565.7 INR
46% Upside
EMCURE Highest Forecast
Wall Street Target
1 732.5 INR
61% Upside
Lowest
Price Target
1 454.4 INR
35% Upside
Average
Price Target
1 565.7 INR
46% Upside
Highest
Price Target
1 732.5 INR
61% Upside
Emcure Pharmaceuticals Ltd Competitors:
Price Targets
CPH
Cipher Pharmaceuticals Inc
52% Upside
1177
Sino Biopharmaceutical Ltd
19% Upside
C
CVKD
Cadrenal Therapeutics Inc
106% Upside
600216
Zhejiang Medicine Co Ltd
35% Upside
CPH
Cipher Pharmaceuticals Inc
52% Upside
1177
Sino Biopharmaceutical Ltd
19% Upside
C
CVKD
Cadrenal Therapeutics Inc
106% Upside
600216
Zhejiang Medicine Co Ltd
35% Upside
600750
Jiang Zhong Pharmaceutical Co Ltd
35% Upside

Revenue
Forecast

Revenue Estimate
Emcure Pharmaceuticals Ltd

For the last 1 year the compound annual growth rate for Emcure Pharmaceuticals Ltd's revenue is 11%. The projected CAGR for the next 3 years is 14%.

11%
Past Growth
14%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Emcure Pharmaceuticals Ltd

For the last 1 year the compound annual growth rate for Emcure Pharmaceuticals Ltd's operating income is 0%. The projected CAGR for the next 3 years is 18%.

0%
Past Growth
18%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Emcure Pharmaceuticals Ltd

For the last 1 year the compound annual growth rate for Emcure Pharmaceuticals Ltd's net income is -6%. The projected CAGR for the next 3 years is 29%.

-6%
Past Growth
29%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
EMCURE intrinsic value, competitors valuation, and company profile.
DCF Valuation
EMCURE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EMCURE stock valuation using valuation multiples.
Wall Street Estimates
EMCURE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EMCURE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EMCURE's stock price target?
Price Target
1 565.7 INR

According to Wall Street analysts, the average 1-year price target for EMCURE is 1 565.7 INR with a low forecast of 1 454.4 INR and a high forecast of 1 732.5 INR.

What is Emcure Pharmaceuticals Ltd's Revenue forecast?
Projected CAGR
14%

For the last 1 year the compound annual growth rate for Emcure Pharmaceuticals Ltd's revenue is 11%. The projected CAGR for the next 3 years is 14%.

What is Emcure Pharmaceuticals Ltd's Operating Income forecast?
Projected CAGR
18%

For the last 1 year the compound annual growth rate for Emcure Pharmaceuticals Ltd's operating income is 0%. The projected CAGR for the next 3 years is 18%.

What is Emcure Pharmaceuticals Ltd's Net Income forecast?
Projected CAGR
29%

For the last 1 year the compound annual growth rate for Emcure Pharmaceuticals Ltd's net income is -6%. The projected CAGR for the next 3 years is 29%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 243,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.